Anticitrulline peptide antibodies (CCP3) in leprosy sera: a negative association.

Anticyclic citrullinated peptide antibodies (anti-CCP) have been described almost exclusively in patients with rheumatoid arthritis. Recently, these autoantibodies have been found in patients with active tuberculosis. Leprosy is another mycobacterial disease where the presence of autoantibodies has been described by several authors. In this study, 64 patients with leprosy (32 paucibacillary and 32 multibacillary forms of the disease) were evaluated and only 2 patients were positive for the presence of anti-CCP. The low frequency of anti-CCP in leprosy sera demonstrated in our study illustrates the high specificity of anti-CCP for the diagnosis of rheumatoid arthritis.
AuthorsLuiz Sergio Guedes-Barbosa, Cristovão Mangueira, Morton Scheinberg
JournalClinical rheumatology (Clin Rheumatol) Vol. 27 Issue 4 Pg. 515-6 (Apr 2008) ISSN: 0770-3198 [Print] Belgium
PMID18087761 (Publication Type: Journal Article)
Chemical References
  • Autoantibodies
  • Biomarkers
  • Peptides, Cyclic
  • cyclic citrullinated peptide
  • Adolescent
  • Adult
  • Arthritis, Rheumatoid (blood, diagnosis, immunology)
  • Autoantibodies (blood)
  • Biomarkers (blood)
  • Diagnosis, Differential
  • Female
  • Humans
  • Leprosy (blood, diagnosis, immunology)
  • Male
  • Middle Aged
  • Peptides, Cyclic (immunology)
  • Sensitivity and Specificity

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: